The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes

Cancer Immunology, Immunotherapy

Volumn 57, Issue 3, 2008, Pages 389-398

  Thompson, James A ^a   Srivastava, Minu K ^a   Bosch, Jacobus J ^a   Clements, Virginia K ^a   Ksander, Bruce R ^b   Ostrand Rosenberg, Suzanne ^a  

^a UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

^b SCHEPENS EYE RESEARCH INSTITUTE   (United States)

Author keywords

Antigen processing and presentation; Cancer vaccines; Major histocompatibility complex class II

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TUMOR PROTEIN;

ALLELE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; BREAST CARCINOMA; BREAST CELL; CD4+ T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIGEN-PRESENTING CELLS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; BREAST NEOPLASMS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FLOW CYTOMETRY; GENETIC VECTORS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; TH1 CELLS;

EID: 37349020263     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0381-5     Document Type: Article

References (48)

1. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S (1997) Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 94:6886-6891
2. + tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181:619-629
3. Belz GT, Wodarz D, Diaz G, Nowak MA, Doherty PC (2002) Compromised influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J Virol 76:12388-12393
4. Benichou G, Takizawa PA, Ho PT, Killion CC, Olson CA, McMillan M, Sercarz EE (1990) Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides. J Exp Med 172:1341-1346
5. Bennett SR, Carbone FR, Karamalis F, Miller JF, Heath WR (1997) Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 186:65-70
6. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478-480
7. Bodmer H, Viville S, Benoist C, Mathis D (1994) Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science 263:1284-1286
8. Bosch JJ, Thompson JA, Srivastava MK, Iheagwara UK, Murray TG, Lotem M, Ksander BR, Ostrand-Rosenberg S (2007) MHC II uveal melanoma vaccines prime and boost CD4+ T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 67:4499-4506
9. Busch R, Cloutier I, Sekaly RP, Hammerling GJ (1996) Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 15:418-428
10. Busch R, Rinderknecht CH, Roh S, Lee AW, Harding JJ, Burster T, Hornell TM, Mellins ED (2005) Achieving stability through editing and chaperoning:regulation of MHC class II peptide binding and expression. Immunol Rev 207:242-260
11. Chamuleau ME, Souwer Y, Van Ham SM, Zevenbergen A, Westers TM, Berkhof J, Meijer CJ, van de Loosdrecht AA, Ossenkoppele GJ (2004) Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res 64:5546-5550
12. Clements VK, Baskar S, Armstrong TD, Ostrand-Rosenberg S (1992) Invariant chain alters the malignant phenotype of MHC class II+ tumor cells. J Immunol 149:2391-2396
13. Dissanayake SK, Thompson JA, Bosch JJ, Clements VK, Chen PW, Ksander BR, Ostrand-Rosenberg S (2004) Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 64:1867-1874
14. Dolan BP, Gibbs KD, Ostrand-Rosenberg S Jr (2006) Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. J Immunol 176:1447-1455
15. Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin BM (2005) Expression of MHC II genes. Curr Top Microbiol Immunol 290:147-170
16. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998
17. Gammon G, Sercarz EE, Benichou G (1991) The dominant self and the cryptic self: shaping the autoreactive T-cell repertoire. Immunol Today 12:193-195
18. Ganss R, Arnold B, Hammerling GJ (2004) Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur J Immunol 34:2635-2641
19. Gao FG, Khammanivong V, Liu WJ, Leggatt GR, Frazer IH, Fernando GJ (2002) Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell. Cancer Res 62:6438-6441
20. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659-662
21. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421:852-856
22. Keene JA, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155:768-782
23. Long EO, Strubin M, Wake CT, Gross N, Carrel S, Goodfellow P, Accolla RS, Mach B (1983) Isolation of cDNA clones for the p33 invariant chain associated with HLA-DR antigens. Proc Natl Acad Sci USA 80:5714-5718
24. Loss GE Jr, Elias CG, Fields PE, Ribaudo RK, McKisic M, Sant AJ (1993) Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J Exp Med 178:73-85
25. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L (1996) H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 84:543-550
26. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, Blay JY (1998) Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 92:4778-4791
27. Menetrier-Caux C, Thomachot MC, Alberti L, Montmain G, Blay JY (2001) IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res 61:3096-3104
28. Muntasell A, Carrascal M, Alvarez I, Serradell L, van Veelen P, Verreck FA, Koning F, Abian J, Jaraquemada D (2004) Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands. J Immunol 173:1085-1093
29. Ostrand-Rosenberg S, Thakur A, Clements V (1990) Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 144:4068-4071
30. Pulaski B, Ostrand-Rosenberg S (1998) MHC class II and B7.1 immunotherapeutic cell-based vaccine reduces spontaneous mammary carcinoma metastases without affecting primary tumor growth. Cancer Res 58:1486-1493
31. Pulaski B, Clements V, Pipeling M, Ostrand-Rosenberg S (2000) Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with IL-12 reduces established metastatic disease and stimulates immune effectors and monokine-induced by interferon-gamma. Canc Immunol Immunother 49:34-45
32. Qi L, Ostrand-Rosenberg S (2000) MHC class II presentation of endogenous tumor antigen by cellular vaccines depends on the endocytic pathway but not H2-M. Traffic 1:152-160
33. Qi L, Rojas JM, Ostrand-Rosenberg S (2000) Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol 165:5451-5461
34. Qin Z, Blankenstein T (2000) CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677-686
35. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63:4095-4100
36. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474-478
37. Rock KL, Shen L (2005) Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 207:166-183
38. Rosenberg SA (2004) Shedding light on immunotherapy for cancer. N Engl J Med 350:1461-1463
39. Schild H, Rotzschke O, Kalbacher H, Rammensee HG (1990) Limit of T cell tolerance to self proteins by peptide presentation. Science 247:1587-1589
40. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480-483
41. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339
42. Sotomayor EM, Borrello I, Rattis FM, Cuenca AG, Abrams J, Staveley-O'Carroll K, Levitsky HI (2001) Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98:1070-1077
43. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95:1178-1183
44. Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339-342
45. Sun JC, Williams MA, Bevan MJ (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5:927-933
46. Tamori Y, Tan X, Nakagawa K, Takai E, Akagi J, Kageshita T, Egami H, Ogawa M (2005) Clinical significance of MHC class II-associated invariant chain expression in human gastric carcinoma. Oncol Rep 14:873-877
47. Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S (2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 66:1147-1154
48. Veenstra H, Jacobs P, Dowdle EB (1996) Abnormal association between invariant chain and HLA class II alpha and beta chains in chronic lymphocytic leukemia. Cell Immunol 171:68-73